Atlas Trials

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Clinical trial NCT00782106 · COMPLETED

Trial details

NCT number
NCT00782106
Sponsor
Baxalta now part of Shire
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Primary Immunodeficiency Diseases (PID)
Start date
2006-12-04
Primary completion
2007-11-01
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.